Patents by Inventor Glenn Mark Anderson

Glenn Mark Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PSMA binding agents and uses thereof
    Patent number: 11746157
    Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: September 5, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
  • PSMA BINDING AGENTS AND USES THEREOF
    Publication number: 20200024360
    Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Application
    Filed: May 21, 2019
    Publication date: January 23, 2020
    Inventors: Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
  • ANTI-ROR1, ANTIBODIES, ROR1 X CD3 BISPECIFIC ANTIBODIES, AND METHODS OF USING THE SAME
    Publication number: 20170210799
    Abstract: Provided herein are isolated antibodies that immunospecifically bind to ROR1, bispecific antibodies comprising an antigen-binding site that immunospecifically binds to ROR1 and an antigen-binding site that immunospecifically binds to CD3, and methods of using the same.
    Type: Application
    Filed: January 19, 2017
    Publication date: July 27, 2017
    Inventors: Glenn Mark ANDERSON, Eric T. BALDWIN, Benjamin HARMAN, Rosa M.F. CARDOSO, Jennifer F. NEMETH-SEAY, Ricardo ATTAR, Francois GAUDET, Yingzhe LI, Jinquan LUO, Ronan MCDAID, Steven C. POMERANTZ, Susan H. TAM, Alexey TEPLYAKOV, Sheng-Jiun WU
  • Human tissue factor antibody and uses thereof
    Patent number: 8999333
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: April 7, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human tissue factor antibody and uses thereof
    Patent number: 8951525
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 10, 2015
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • HUMAN TISSUE FACTOR ANTIBODY AND USES THEREOF
    Publication number: 20140234304
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicant: Janssen Biotech, Inc.
    Inventors: Juan Carlos ALMAGRO, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human tissue factor antibody and uses thereof
    Patent number: 8722044
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: May 13, 2014
    Assignee: Janssen Biotech, Inc.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20130189250
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 25, 2013
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • Human Tissue Factor Antibody and Uses Thereof
    Publication number: 20120237528
    Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
    Type: Application
    Filed: February 17, 2012
    Publication date: September 20, 2012
    Inventors: Juan Carlos Almagro, Glenn Mark Anderson, Ellen Chi, Christian Martinez, Gopalan Raghunathan, Ronald Swanson, Alexey Teplyakov, Kam-Fai Tse, Sheng-Jiun Wu, Hong Mimi Zhou
  • sRAGE mimetibody, compositions, methods and uses
    Patent number: 8043616
    Abstract: Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: October 25, 2011
    Assignee: Centocor, Inc.
    Inventors: Glenn Mark Anderson, Robert Jordan, Kristen Picha
  • sRAGE Mimetibody, Compositions, Methods and Uses
    Publication number: 20090098122
    Abstract: Mammalian sRAGE mimetibody polypeptides and nucleic acids are disclosed. Methods of utilizing the polypeptides to reduce or inhibit the binding of RAGE and its ligands and to treat RAGE-related diseases are also disclosed.
    Type: Application
    Filed: July 17, 2008
    Publication date: April 16, 2009
    Inventors: Glenn Mark Anderson, Robert Jordan, Kristen Picha
  • LL-37 is an immunostimulant
    Publication number: 20040013679
    Abstract: The present invention provides a method of enhancing an immune response in a subject, comprising administering an effective amount of LL-37. Moreover, the present invention provides a method of enhancing in a subject an immune response to a vaccine, comprising administering to the subject an effective amount of LL-37 with a vaccine. Further provided is a method of detecting a compound that decreases an immune response in a subject. A method of treating an autoimmune disease in a subject is thus provided. Also provided is a vaccine comprising an immunogen and LL-37.
    Type: Application
    Filed: July 14, 2003
    Publication date: January 22, 2004
    Inventors: Oleg Chertov, De Yang, Glenn Mark Anderson, Joseph Wooters, Joost J. Oppenheim